Acrivon Therapeutics, Inc. 8-K

What Happened Acrivon Therapeutics, Inc. (ACRV) filed a Form 8-K on March 19, 2026 reporting its financial results for the quarter and full year ended December 31, 2025 and furnishing a press release (Exhibit 99.1). The company also posted an updated corporate presentation on its investor site (Exhibit 99.2) that discloses pipeline updates, including the initiation of arm 4 of the registrational-intent ACR-368 Phase 2b study for ACR-368 monotherapy in serous-type endometrial cancer. Management cited promising clinical data and observed OncoSignature biomarker upregulation as the basis for starting arm 4.

Key Details

• Filing date: March 19, 2026; financial results cover quarter and full year ended December 31, 2025.
• Exhibits: Press release (Exhibit 99.1) and Corporate Presentation (Exhibit 99.2) were furnished with the 8-K.
• ACR-368 Phase 2b updates: Arm 4 initiated to study ACR-368 monotherapy in serous endometrial cancer patients with ≤2 prior lines of therapy.
• Exploratory Arm 2 completed: treated OncoSignature biomarker-negative (BM-) subjects (≤3 prior lines) with ACR-368 plus ultra low dose gemcitabine (ULDG); objectives were met and data support a potential role for ULDG with a favorable tolerability profile.

Why It Matters For investors, the 8-K confirms both routine earnings disclosure and meaningful clinical progress for Acrivon’s lead program, ACR-368. Initiation of a registrational-intent arm (arm 4) signals advancement toward potential registration-directed data in a defined endometrial cancer population, supported by biomarker findings. Completion of exploratory arm 2 and the corporate presentation provide additional clinical and tolerability context that may influence the company’s development timeline and investor expectations.